← All drugs Report issue

emineurina

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

1

Phase 3

1

Phase 4

0

Earliest trial started Jan 1, 2015 (NCT02374567)

Timeline

2010s

Jan 1, 2015
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

GABA-A receptor; anion channelPOSITIVE ALLOSTERIC MODULATOR
GABA-A receptor; anion channel positive allosteric modulator
Chlomethiazole allosterically enhances GABAA receptor conductance and has been shown to be neuroprotective in animal models of both global and focal ischemia.
Barbiturate site

Chemistry & pharmacology

Loading structure…

SMILES

Cc1ncsc1CCCl

Mol. weight: 161.66 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL315795 ↗

Also known as

chlorethiazol
chlorethiazole
chlormethiazol
chlormethiazole
chlormethiazole
chlormethiazole
chlormethiazole
chlormethiazole
chlormethiazole ethanedisulfonate
chlormethiazole hcl
chlormethiazole hydrochloride
clomethiazole
clomethiazole
clomethiazole
clomethiazole
clomethiazole
clomethiazole
clomethiazole edisilate
clomethiazole edisylate
clomethiazolum
distraneurin
emineurina
heminevrin
heminevrin
heminevrin
sctz [as edisylate]
sctz [as edisylate]

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02374567	Phase 3	Jan 1, 2015	Gottfried Wilhelm Leibniz Universität Hannover

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Gottfried Wilhelm Leibniz Universität Hannover	Academic/Hospital	1	1	1	2015

1 organizations

Page 1 / 1